Sutro Biopharma, Inc. (STRO)
15.34
-0.14
(-0.90%)
USD |
NASDAQ |
Sep 18, 16:00
15.32
-0.02
(-0.13%)
After-Hours: 20:00
Sutro Biopharma Cash from Investing (Quarterly) : 19.36M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.36M |
| March 31, 2026 | -45.26M |
| December 31, 2025 | 18.70M |
| September 30, 2025 | 39.99M |
| June 30, 2025 | 2.58M |
| March 31, 2025 | -16.26M |
| December 31, 2024 | 87.49M |
| September 30, 2024 | 147.29M |
| June 30, 2024 | -80.38M |
| March 31, 2024 | 64.10M |
| December 31, 2023 | -23.51M |
| September 30, 2023 | -114.02M |
| June 30, 2023 | 66.16M |
| March 31, 2023 | 67.45M |
| December 31, 2022 | -37.88M |
| September 30, 2022 | -78.04M |
| June 30, 2022 | 47.92M |
| March 31, 2022 | 32.98M |
| Date | Value |
|---|---|
| December 31, 2021 | 20.78M |
| September 30, 2021 | -2.242M |
| June 30, 2021 | 5.876M |
| March 31, 2021 | -121.73M |
| December 31, 2020 | 15.81M |
| September 30, 2020 | 0.296M |
| June 30, 2020 | -57.14M |
| March 31, 2020 | 41.64M |
| December 31, 2019 | 7.942M |
| September 30, 2019 | 9.812M |
| June 30, 2019 | 9.194M |
| March 31, 2019 | -78.08M |
| December 31, 2018 | 2.025M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 1.63M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Upstream Bio, Inc. | 15.76M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -38.29M |
| Cash from Financing (Quarterly) | -0.418M |
| Free Cash Flow | -145.62M |
| Free Cash Flow Per Share (Quarterly) | -2.311 |
| Free Cash Flow to Equity (Quarterly) | -45.40M |
| Free Cash Flow to Firm (Quarterly) | -28.43M |
| Free Cash Flow Yield | -81.26% |